The anti-EGFR antibodies cetuximab and panitumumab have been labeled with various radionuclides and evaluated as nuclear medicine-based imaging agents in a dozen of preclinical and clinical studies for HNSCC. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.